PMID- 24390604
OWN - NLM
STAT- MEDLINE
DCOM- 20140910
LR  - 20220330
IS  - 1613-2246 (Electronic)
IS  - 0021-5155 (Linking)
VI  - 58
IP  - 2
DP  - 2014 Mar
TI  - Incidence of deepening of the upper eyelid sulcus on treatment with a tafluprost 
      ophthalmic solution.
PG  - 212-7
LID - 10.1007/s10384-013-0299-8 [doi]
AB  - PURPOSE: Deepening of the upper eyelid sulcus (DUES), one symptom of 
      prostaglandin-associated periorbitopathy, was recently found to be an additional 
      side effect of prostaglandin-related ophthalmic solutions. Here, we prospectively 
      investigated the incidence and factors associated with DUES in Japanese 
      open-angle glaucoma patients initially treated with benzalkonium chloride 
      (BAK)-preserved tafluprost (TAF). METHODS: In this open-label prospective study 
      instilling TAF in one eye, mean deviation (MD) and intraocular pressure (IOP) 
      were measured, and facial photographs and subjective reports of DUES were 
      obtained at intervals over 6 months. Three ophthalmologists independently 
      assessed the photographs of DUES and reached consensus. Relationships between 
      demographic and ocular/systemic factors (age, sex, MD, refraction and IOP 
      reduction) and DUES occurrence were evaluated. RESULTS: Forty-three eyes of 43 
      glaucoma patients (24 men and 19 women) were evaluated. Mean IOP before treatment 
      was 16.6 +/- 2.7 and after treatment, 14.1 +/- 2.3 mmHg (P < 0.001). The objective 
      rate of DUES was 9 % (4/43) at 2 months, 14 % (6/43) at 4 months and 14 % (6/43) 
      at 6 months. During this period, only one patient self-reported an occurrence of 
      DUES. No significant association was found between DUES occurrence and any of the 
      demographic, ocular, or systemic factors. CONCLUSIONS: Physicians should inform 
      patients about DUES as a minor side effect when prescribing TAF for IOP control.
FAU - Sakata, Rei
AU  - Sakata R
AD  - Department of Ophthalmology, Tokyo Metropolitan Geriatric Hospital, University of 
      Tokyo, 35-2, Sakaecho, Itabashi, Tokyo, 173-0015, Japan, 
      reisakata-tky@umin.ac.jp.
FAU - Shirato, Shiroaki
AU  - Shirato S
FAU - Miyata, Kazunori
AU  - Miyata K
FAU - Aihara, Makoto
AU  - Aihara M
LA  - eng
PT  - Journal Article
DEP - 20140107
PL  - Japan
TA  - Jpn J Ophthalmol
JT  - Japanese journal of ophthalmology
JID - 0044652
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Ophthalmic Solutions)
RN  - 0 (Preservatives, Pharmaceutical)
RN  - 0 (Prostaglandins F)
RN  - 1O6WQ6T7G3 (tafluprost)
SB  - IM
MH  - Antihypertensive Agents/administration & dosage/*adverse effects
MH  - Eyelid Diseases/*chemically induced
MH  - Female
MH  - Glaucoma, Open-Angle/*drug therapy
MH  - Humans
MH  - Incidence
MH  - Intraocular Pressure/drug effects
MH  - Low Tension Glaucoma/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Ophthalmic Solutions
MH  - Orbital Diseases/*chemically induced
MH  - Preservatives, Pharmaceutical
MH  - Prospective Studies
MH  - Prostaglandins F/administration & dosage/*adverse effects
EDAT- 2014/01/07 06:00
MHDA- 2014/09/11 06:00
CRDT- 2014/01/07 06:00
PHST- 2013/07/06 00:00 [received]
PHST- 2013/12/02 00:00 [accepted]
PHST- 2014/01/07 06:00 [entrez]
PHST- 2014/01/07 06:00 [pubmed]
PHST- 2014/09/11 06:00 [medline]
AID - 10.1007/s10384-013-0299-8 [doi]
PST - ppublish
SO  - Jpn J Ophthalmol. 2014 Mar;58(2):212-7. doi: 10.1007/s10384-013-0299-8. Epub 2014 
      Jan 7.